Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Koury LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, Salinas V, Muxi P, Melo RAM, Gloria ABF, Pagnano KBB, Nunes EC, Bittencourt RI, Rojas N, Quintana Truyenque SM, Ayala-Lugo AI Dr, Oliver AC, de Figueiredo-Pontes LL, Traina F, Moreira F, Fagundes EM, Duarte BKL, Mora-Alferez AP, Ortiz P, Untama JL, Tallman MS, Ribeiro RC, Ganser A, Dillon RJ, Valk PJM, Sanz MA, Löwenberg B, Berliner N, Rego EM. Koury LCA, et al. Among authors: dillon rj. Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890. Online ahead of print. Blood. 2024. PMID: 38805638
Recommendations from the AML molecular MRD expert advisory board.
Scott S, Devonshire A, Dillon R, Thiede C, Cross NCP, White HE, Lo Cascio L, Mokretar K, Potter N, Hourigan CS, Radich J, Corner A, Laloux V, Halliday G, Dilks D, Morrison T, Gilmour K, Cartwright A, Whitby L. Scott S, et al. Among authors: dillon r. Leukemia. 2024 May 23. doi: 10.1038/s41375-024-02275-x. Online ahead of print. Leukemia. 2024. PMID: 38783160 No abstract available.
Functional Grading Between Soft-Magnetic Fe-Co/Fe-Ni Alloys and the Effect on Magnetic and Microstructural Properties.
Adamczyk JM, Barrick EJ, Pearce CJ, Delaney RE, Ury N, Dillon RP, Monson TC, Carroll JD, Susan DF, Valdez NR, Lang E, Hattar K, Love AS, Choi H, Kustas AB, Firdosy SA. Adamczyk JM, et al. Among authors: dillon rp. ACS Appl Eng Mater. 2024 Mar 21;2(4):818-828. doi: 10.1021/acsaenm.3c00564. eCollection 2024 Apr 26. ACS Appl Eng Mater. 2024. PMID: 38737588 Free PMC article.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes AF, Gale RE, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh JD, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett AK -, Wilhelm-Benartzi CS, Huntly BJ, Russell NH, Dillon RJ. Othman J, et al. Among authors: dillon rj. Blood. 2024 May 1:blood.2024024310. doi: 10.1182/blood.2024024310. Online ahead of print. Blood. 2024. PMID: 38691678
Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
Khan AA, James D, Andresen V, Atkey J, Bradbury R, Cargo C, Dillon R, Gjertsen BT, Goldstone AR, Leach R, Lock D, Narayanan M, Russell N, Verigou EA, Green S, Fielding AK, Falini B. Khan AA, et al. Among authors: dillon r. Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301. Online ahead of print. Am J Hematol. 2024. PMID: 38567798 No abstract available.
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Tiong IS, Hiwase DK, Abro E, Bajel A, Palfreyman E, Beligaswatte A, Reynolds J, Anstee N, Nguyen T, Loo S, Chua CC, Ashby M, Wiltshire KM, Fleming S, Fong CY, Teh TC, Blombery P, Dillon R, Ivey A, Wei AH. Tiong IS, et al. Among authors: dillon r. J Clin Oncol. 2024 Mar 1:JCO2301599. doi: 10.1200/JCO.23.01599. Online ahead of print. J Clin Oncol. 2024. PMID: 38427924
381 results